摘要
目的分析循环miR-152与miR-221在前列腺癌患者血清中的表达水平及临床意义。方法收集2009年1月-2013年4月本院泌尿外科收治的前列腺癌患者48例,前列腺良性增生患者32例,并招募同期健康体检者24例作为对照组,分析各组血清中miR-152与miR-221的表达水平及与PSA、Gleason的相关性关系。结果前列腺癌患者中miR-152的表达量显著低于正常人群和前列腺良性增生患者(P<0.05),前列腺良性增生和正常对照组之间差异无统计学意义(P>0.05);miR-221在前列腺癌患者中的表达量显著低于正常人群和前列腺良性增生患者,且前列腺良性增生患者中的表达量也较正常人群低,差异均有统计学意义(P<0.05);前列腺癌患者miR-152血清表达水平与Gleason评分之间存在显著负相关性(P<0.05),与血清PSA水平无相关性(P>0.05),miR-221血清表达水平与血清PSA及Gleason评分之间存在显著负相关性(P<0.05)。结论 miR-152及miR-221可能通过复杂的调控过程参与前列腺癌的发生、侵袭与转归,为前列腺癌的早期诊断及病程的判断提供了实验依据。
Objective To analysis serum expression levels and clinical significance of circulating miR-152 and miR-221 in prostate cancer patients. Methods From Jan. 2009 to Mar. 2013,48 prostate cancer patients,32 patients with benign prostatic hyperplasia from the unirary surgery in out hospital and 24 healthy volunteers over the same period as a control group were choosen to analyze the expression levels of serum miR-152,miR-221 and the correlation between PSA and Gleason. Results The expression of miR-152 in prostate cancer patients was significantly lower than the normal population and the patients with benign prostatic hyperplasia,there was no statistically significance for difference between benign prostatic hyperplasia and normal control group( P 0. 05); miR-221 expression levels in prostate cancer patients was significantly lower than the normal population and in patients with benign prostatic hyperplasia,the expression level in benign prostatic hyperplasia was also lower than the normal population,and the differences were statistically significant( P 0. 05). The expression level of miR-152 in prostate cancer patients were significant negative correlation with Gleason score( P 0. 05),but there was no correlation with serum PSA levels( P 0. 05),the expression level of miR-221 in prostate cancer patients had significant negative correlation with serum PSA and Gleason score. Conclusion MiR-152 and miR-221 may be involved in prostate through complex regulatory process,invasion and provides an experimental basis for early diagnosis of prostate cancer and determine the course.
出处
《中国卫生检验杂志》
CAS
2015年第5期673-675,679,共4页
Chinese Journal of Health Laboratory Technology
基金
宁波市自然科学基金项目(2010A610051)